从发现到临床开发

审阅要点

请在原始来源中核对模型、人群、对照、终点和制剂。某一阶段或制剂的结果不能自动适用于其他情况或目录材料。

请提供产品或序列、配置、数量、目的地和所需文档，以便团队评估范围并确认可提供的信息。

科学文献 · S02

Xiao et al. · Signal Transduction and Targeted Therapy

来源详情（原文语言）

范围: Historical review reporting 28 approvals in 2014–2024 and 38 phase III candidates
文件位置: Peptide-based drug market & clinical trial; Figure 4 and Tables 2–3
局限: Denominators differ between narrative and tables; no new percentages or current regulatory count inferred.
陈述核实日期: 2026-09-09

科学文献 · S04

Wang et al. · Signal Transduction and Targeted Therapy

来源详情（原文语言）

范围: Review of therapeutic peptide development
文件位置: Introduction; production, modification and applications
局限: Historical review, not validation of products or batches. More than 80 approved drugs is a 2022 literature statement.
陈述核实日期: 2026-09-09

官方／监管来源 · R01

FDA

来源详情（原文语言）

范围: US approval of Zepbound (tirzepatide) for the stated adult indication
文件位置: Zepbound approval announcement
局限: Approval applies to that medicinal product and jurisdiction, not research vials.
陈述核实日期: 2026-09-09